OIA House
4th Floor 470, Cardinal Gracious Road Andheri (East)
Mumbai 400099
India
91 22 6829 7979
https://www.glenmarklifesciences.com
Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - Specialty & Generic
Employés à temps plein:
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Yasir Yusufali Rawjee Ph.D. | CEO, MD & Director | 54,97M | S.O. | 1965 |
Mr. Tushar P. Mistry | Senior VP & CFO | S.O. | S.O. | S.O. |
Mr. Rudalf Corriea | Company Secretary & Compliance Officer | S.O. | S.O. | S.O. |
Mr. Sumantra Mitra | Head of Human Resources | 18,2M | S.O. | S.O. |
Mr. Vinod Naik | Group VP, Head of Technical Operations & Whole Time Director | 28,1M | S.O. | S.O. |
Soumi Rao | General Manager of Corporate Communications | S.O. | S.O. | S.O. |
Mr. Mathew George | VP & Head of Regulatory Affairs | S.O. | S.O. | S.O. |
Mr. Navin Kumar Agrawal | Head of Corporate Quality -API | S.O. | S.O. | S.O. |
Glenmark Life Sciences Limited engages in the development, manufacture, and supply of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. It offers Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, and Cilostazol for the treatment of cardiovascular disease; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for the treatment of central nervous system disease; Remogliflozin, Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin for the treatment of diabetes; Etoricoxib, Lornoxicam, Zolmitriptan, and Frovatriptan for pain management; and Olaparib, Palbociclib, Enzalutamide, and Ruxolitinib for oncology treatment, as well as Atovaquone, an anti-parasitic and Adapalene, a dermatology product. The company also provides contract development and manufacturing services to a range of multinational pharmaceutical and specialty pharmaceutical companies. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited operates as a subsidiary of Nirma Limited.
L’ISS Governance QualityScore de Glenmark Life Sciences Limited en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..